360Dx

Ambry Genetics, Caris Life Sciences Partner on Cancer Genetic Testing

Dec 04, 2019

NEW YORK – Ambry Genetics and Caris Life Sciences today announced a partnership on cancer genetic testing in the US.

Under the terms of the agreement, Caris will offer Ambry's 67-gene CancerNext-Expanded gene panel to evaluate hereditary risk of cancer alongside its Caris Molecular Intelligence tumor profiling.

Financial and other terms of the partnership were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Ambry Genetics, Caris Life Sciences Partner on Cancer Genetic Testing

To read the full story....

Breaking News

Biden Administration Funds $1B for COVID-19 Testing in Indian Country

Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

NIH Awards Qorvo Biotechnologies $24.4M for Rapid SARS-CoV-2 Antigen Test

In Brief This Week: Exact Sciences, Siemens Healthineers, Seegene, Agilent Technologies, and More

Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

Featured White Papers

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

What's Popular?

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

Arcedi Biotech Introduces NIPT Analyzing DNA From Rare Fetal Cells in Maternal Blood

FDA-Led Group Evaluates Performance of RUO Liquid Biopsy Assays to Inform Practice Guidelines

Sponsorships